Uroplasty Reports Financial Results for the Second Quarter FY2011

Global sales increase 9%; U.S. Macroplastique sales grow 50%

Sales to U.S. customers up 23%

Conference call today at 3:30 p.m. CT

Oct 27, 2010, 16:02 ET from Uroplasty, Inc.

MINNEAPOLIS, Oct. 27 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second fiscal quarter ended September 30, 2010.  Global sales grew 9% driven primarily by a 50% increase in Macroplastique product sales in the U.S.

"We reported a 9% increase in revenue in the seasonally weakest quarter of the year, while making substantial progress in positioning the Company for the relaunch of Urgent PC with the availability of the new CPT code early next year," said David Kaysen, President & CEO of Uroplasty, Inc.  "Growth in sales to U.S. customers of 23% was driven by our renewed focus on Macroplastique, as well as an increase in sales of Urgent PC.  Sales outside the U.S., excluding currency translations, were up 4% from the same quarter the prior year."

"Late in our fiscal second quarter, we announced that five regional Medicare carriers planned to initiate coverage and payment for Posterior Tibial Nerve Stimulation (PTNS), using our Urgent PC system.  Given the time the carriers require to implement this coverage, including the programming of computers to accept electronic claims, as well as the desire on the part of physicians to start slowly with submitting claims to insure payment, we saw little revenue contribution from this development for the period.

"In anticipation of the establishment of a new CPT code and reimbursement rates for the Urgent PC procedure, we are moving forward on our plan to build our sales force and complete the training and other efforts necessary to drive awareness and sales of Urgent PC.  We have doubled the number of sales reps from 15 at the start of our fiscal year to 30, who have either officially joined Uroplasty or have accepted positions with the company and are scheduled to be on board by early November.  We have also added three field reimbursement specialists and are looking for a fourth.  With the four field sales managers already in place, we are well on our way to building the sales organization we believe we need to execute a successful marketing effort for Urgent PC.  We anticipate that the new CPT code number and reimbursement rates will be assigned and published in the Federal Register by the Centers for Medical and Medical Services (CMS) very shortly and we want to be well-positioned to move forward as quickly as possible to educate physicians and consumers about the benefits of our procedure," Mr. Kaysen added.

Fiscal Second Quarter and First Half Results for the Period Ended September 30, 2010

Net sales for the three months ended September 30, 2010 totaled $3.2 million, an increase of 9% over net sales of $3.0 million for the same quarter of the prior fiscal year.  Excluding the translation impact of foreign currency exchange rates, sales increased by approximately 13%. For the six months ended September 30, 2010, net sales were $6.3 million, 8% above net sales for the comparable period of 2009 of $5.8 million.  Excluding the impact of foreign exchange translation, sales grew by 12%.

Sales to customers in the U.S. for the three months ended September 30, 2010 were $1.8 million, a 23% increase compared to $1.5 million in net sales for the year-ago quarter.  During the first half of fiscal 2011, sales to customers in the U.S. totaled $3.5 million, representing a 17% increase over net sales of $3.0 million for the six month period of fiscal 2010.

Sales in the U.S. of the Urgent PC product for the three months ended September 30, 2010 increased 6% to $1.0 million compared with $960,000 for the same period last year.  This was at the high end of the recent range of quarterly sales between $900,000 and $1.0 million.  For the recent six month period, sales from Urgent PC totaled $1.9 million, a decline of 3% from $2.0 million for the comparable period last year.

Sales in the U.S. of Macroplastique increased 50% to $791,000 for the three months ended September 30, 2010, from $528,000 for the same period last year.  For the six months of fiscal 2011, sales of Macroplastique increased 58% to $1.5 million versus $949,000 in the same period a year ago.  The growth in Macroplastique product sales reflects the increased sales and marketing focus on this product line as well as competitive benefits that have been highlighted by independent reviews.

Net sales to customers outside of the U.S. for the three months ended September 30, 2010 were $1.4 million, a decrease of 6% from $1.5 million in the same quarter last year.  Excluding the impact of foreign exchange translation, sales increased by approximately 4%.  For the six months ended September 30, 2010, sales of $2.8 million were roughly unchanged from the comparable period of the prior year.  Excluding the impact of foreign exchange translation, sales increased by approximately 7%.

The operating loss for the fiscal second quarter ended September 30, 2010 was $947,000 compared with $877,000 in the prior year. The operating loss, excluding non-cash charges for share-based compensation and depreciation and amortization, of $591,000 in the recent second quarter increased from approximately $475,000 in the year-ago quarter, primarily due to increased spending because of higher bonuses, commissions, increase in headcount and consulting expenses.  The net loss for the three months ended September 30, 2010 was $923,000, or $0.05 per diluted share, as compared to a net loss of $875,000, or $0.06 per diluted share, for the quarter ended September 30, 2009.

Cash and cash equivalents and short-term investments at September 30, 2010 totaled $21.4 million.  Reflected in the total was the contribution from the proceeds of a recently completed public offering of common shares.  In July 2010, the company issued 4.6 million shares at $3.50 per share, for net proceeds of approximately $14.9 million.  The company plans to use the proceeds to expand the U.S. sales and marketing organizations to support the Urgent PC business, and for clinical studies, working capital and general corporate purposes.  Following completion of the public offering, the company has 20.5 million common shares outstanding.

"With the additional capital raised through the offering, we have the funds necessary to execute our plan to drive sales growth and move toward profitability," continued Mr. Kaysen.  "While we are managing this cash very carefully, over the next couple of quarters, we expect to increase our investments in building our marketing and sales effort in support of our relaunch of Urgent PC.  In addition, we intend to explore the emerging opportunity in the U.S. to treat fecal incontinence using the Urgent PC, which has already received a CE Mark for treatment of fecal incontinence in Europe.  With the opportunities ahead for Urgent PC and the momentum in Macroplastique sales supported by a strong balance sheet, we are excited about the outlook for the company."

Conference Call

Uroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the second fiscal quarter ended September 30, 2010. David Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer will host the call. Individuals wishing to participate in the conference call should dial 877-941-6012. An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) or 303-590-3030 (international), with the passcode 4374726#.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that the CPT Code for the PTNS procedures in which Urgent PC is used will be timely published, that the rate of reimbursement for such procedures will be adequate to justify the cost of our product, that the amount and rate at which we apply funds to expand our sales force will be justified by increased sales, that larger competitors will not introduce products or pharmaceuticals that target the portion of the market for which Urgent PC is designed, that sales of our Macroplastique product will continue to increase, that percutaneous nerve stimulation will ever be an accepted, and FDA-cleared, procedure for the treatment of fecal incontinence, or that if it is, it will be reimbursed by private and governmental payers, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements .

For Further Information:

Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors)

Medi Jiwani, Vice President, CFO, and

415.896.6820

Treasurer

Chris Gale (Media)

952.426.6140

646.201.5431

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

September 30,

Six Months Ended

September 30,

2010

2009

2010

2009

Net sales

$3,244,823

$2,986,475

$6,280,322

$5,812,404

Cost of goods sold

594,469

535,074

1,105,165

1,087,044

Gross profit

2,650,354

2,451,401

5,175,157

4,725,360

Operating expenses

    General and administrative

897,368

713,040

1,747,685

1,561,591

    Research and development

472,008

435,898

872,637

963,713

    Selling and marketing

2,017,420

1,968,054

4,005,946

4,025,342

    Amortization

210,682

211,503

421,450

423,316

3,597,478

3,328,495

7,047,718

6,973,962

Operating loss

(947,124)

(877,094)

(1,872,561)

(2,248,602)

Other income (expense)

    Interest income

17,999

24,230

31,627

55,629

    Interest expense

(1,938)

(1,788)

(3,885)

(9,694)

    Foreign currency exchange gain (loss)

10,574

(7,365)

12,364

(14,697)

    Other, net

-

2,000

(192)

(183)

26,635

17,077

39,914

31,055

Loss before income taxes

(920,489)

(860,017)

(1,832,647)

(2,217,547)

Income tax expense

2,183

14,642

19,333

22,887

Net loss

$(922,672)

$(874,659)

$(1,851,980)

$(2,240,434)

Basic and diluted loss per common share

$(0.05)

$(0.06)

$(0.11)

$(0.15)

Weighted average common shares outstanding:

    Basic and diluted

19,088,249

14,946,540

17,207,957

14,942,179

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2010

March 31, 2010

Assets

Current assets:

Cash and cash equivalents & short-term investments

$21,387,687

$5,811,269

Accounts receivable, net

1,492,279

1,287,440

Inventories

472,584

341,497

Income tax receivable

-

23,820

Other

318,808

237,321

Total current assets

23,671,358

7,701,347

Property, plant, and equipment, net

1,186,372

1,230,771

Intangible assets, net

2,122,945

2,533,095

Deferred tax assets

115,026

108,530

Total assets

$27,095,701

$11,573,743

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable

$487,114

$485,594

Current portion – deferred rent

35,000

35,000

Income tax payable

12,433

10,000

Accrued liabilities:

Compensation

952,835

903,057

Other

264,578

212,028

    Total current liabilities

1,751,960

1,645,679

    Deferred rent – less current portion

94,886

112,500

    Accrued pension liability

556,124

601,037

    Total liabilities

2,402,970

2,359,216

    Total shareholders' equity

24,692,731

9,214,527

    Total liabilities and shareholders' equity

$27,095,701

$11,573,743

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months Ended

September 30,

2010

2009

Cash flows from operating activities:

Net loss

$(1,851,980)

$(2,240,434)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

567,576

567,238

Loss on disposal of equipment

192

186

Share-based consulting expense

8,202

-

Share-based compensation expense

140,490

291,462

Deferred income taxes

(4,925)

(3,249)

Deferred rent

(17,614)

(17,462)

Changes in operating assets and liabilities:

Accounts receivable

(187,514)

91,206

Inventories

(125,674)

47,499

Other current assets and income tax receivable

(57,949)

(102,998)

Accounts payable

1,196

(185,406)

Accrued liabilities

94,179

(348,419)

Accrued pension liability, net and income tax payable

(48,246)

(58,492)

Net cash used in operating activities

(1,482,067)

(1,958,869)

Cash flows from investing activities:

Proceeds from sale of short-term investments

2,500,000

2,500,000

Purchase of short-term investments

(5,000,000)

(2,000,000)

Purchases of property, plant and equipment

(94,506)

(61,334)

Purchases of intangible assets

(11,300)

-

Proceeds from sale of property, plant and equipment

-

2,000

Net cash (used in) provided by investing activities

(2,605,806)

440,666

Cash flows from financing activities:

    Net proceeds from public offering of common stock

14,917,059

-

    Net proceeds from warrant and option exercise

2,275,906

-

Net cash provided by financing activities

17,192,965

-

Effect of exchange rates on cash and cash equivalents

(28,674)

34,771

Net increase (decrease)  in cash and cash equivalents

13,076,418

(1,483,432)

Cash and cash equivalents at beginning of period

2,311,269

3,276,299

Cash and cash equivalents at end of period

$15,387,687

$1,792,867

Supplemental disclosure of cash flow information:

Cash paid during the period for interest

$-

$6,145

Cash received(paid) during the period for income taxes

248

(105,877)

Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended September 30, 2010 and 2009 was approximately $591,000 and $475,000, respectively.  Our non-GAAP operating loss during the six months ended September 30, 2010 and 2009 was approximately $1.2 million and $1.4 million, respectively.

Three Months Ended

September 30,

Six Months Ended

September 30,

2010

2009

2010

2009

Gross Profit

  GAAP gross profit

$2,650,354

$2,451,401

$5,175,157

$4,725,360

% of sales

82%

82%

82%

81%

  Share-based compensation

4,184

4,903

8,667

18,448

  Depreciation expense

15,766

14,150

31,464

28,299

  Non-GAAP gross profit

2,670,304

2,470,454

5,215,288

4,772,107

Operating Expenses

  GAAP operating expenses

3,597,478

3,328,495

7,047,718

6,973,962

  Share-based compensation

68,241

113,909

140,024

273,014

  Depreciation expense

57,074

57,546

114,662

115,623

  Amortization expense

210,682

211,503

421,450

423,316

  Non-GAAP operating expenses

3,261,481

2,945,537

6,371,582

6,162,009

Operating Loss

  GAAP operating loss

(947,124)

(877,094)

(1,872,561)

(2,248,602)

  Share-based compensation

72,425

118,812

148,692

291,462

  Depreciation expense

72,840

71,696

146,126

143,922

  Amortization expense

210,682

211,503

421,450

423,316

  Non-GAAP operating loss

$(591,177)

$(475,083)

$(1,156,293)

$(1,389,902)

SOURCE Uroplasty, Inc.



RELATED LINKS

http://www.uroplasty.com